Sugi Predict

Sugi Predict / Compounds / SCHEMBL787142

SCHEMBL787142

SCHEMBL787142

Nc1nc2c(N)nc3ccccc3c2[nH]1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ QTRT1 Q9BXR0 1/20 0.51
▸ TYMS P04818 1/20 0.47
▸ TLR7 Q9NYK1 5/20 0.45
▸ TLR8 Q9NR97 4/20 0.45
▸ ALDH1A1 P00352 4/20 0.44
▸ KMT2A Q03164 2/20 0.44
▸ DCPS Q96C86 1/20 0.44
▸ MASP2 O00187 1/20 0.44
▸ MEN1 O00255 1/20 0.44
▸ NUDT1 P36639 1/20 0.44
▸ AOC3 Q16853 1/20 0.44
▸ ADORA3 P0DMS8 2/20 0.44
▸ ADORA2A P29274 1/20 0.44
▸ ADORA1 P30542 1/20 0.44
▸ KDM4E B2RXH2 3/20 0.44
▸ HPGD P15428 3/20 0.44
▸ HSD17B10 Q99714 3/20 0.44
▸ GLA P06280 2/20 0.44
▸ CASP1 P29466 2/20 0.44
▸ CASP7 P55210 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5335436 0.83 TLR7 (0.50) QTRT1TLR7TLR8ALDH1A1DCPS
SCHEMBL841735 0.83 QTRT1 (0.49) QTRT1TYMSALDH1A1KMT2ADCPS
SCHEMBL212367 0.80 ADORA2A (0.45) QTRT1TLR7TLR8DCPSADORA3
SCHEMBL8600371 0.79 TNKS2 (0.53) TLR7TLR8ALDH1A1ADORA3ADORA2A
SCHEMBL8726003 0.78 KMT2A (0.54) TLR7TLR8ALDH1A1KMT2AKDM4E
SCHEMBL212305 0.77 ALDH1A1 (0.42) QTRT1TLR7TLR8ALDH1A1DCPS
SCHEMBL9036182 0.77 TLR7 (0.52) TLR7TLR8ALDH1A1ADORA3ADORA2A
Hydrochloric Acid SCHEMBL8723782 0.77 KMT2A (0.52) TLR7TLR8ALDH1A1KMT2AKDM4E
SCHEMBL212373 0.77 TLR8 (0.46) TLR7TLR8KMT2ANUDT1ADORA2A
SCHEMBL842050 0.76 PRMT5 (0.42) TYMSALDH1A1KMT2AMASP2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11827694-B2 RSV F protein compositions and methods for making same GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2023-11-28 — — US disclosed
US-20230357370-A1 RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2023-11-09 — — US disclosed
US-20230348575-A1 RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2023-11-02 — — US disclosed
US-20230303669-A1 RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2023-09-28 — — US disclosed
US-20220340645-A1 RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2022-10-27 — — US disclosed
EP-2667892-A1 RSV IMMUNIZATION REGIMEN Novartis AG (CH) 2013-12-04 — — EP disclosed
WO-2013108272-A2 BLOOD STAGE MALARIA VACCINE INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY (IN) 2013-07-25 — — WO disclosed
US-8377957-B2 Hydroxy and alkoxy substituted 1H-imidazoquinolines and methods 3M INNOVATIVE PROPERTIES COMPANY (US) 2013-02-19 — — US disclosed
WO-2012103361-A1 RSV IMMUNIZATION REGIMEN NOVARTIS AG (CH) 2012-08-02 — — WO disclosed
EP-2453918-A2 RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME Novartis AG (CH) 2012-05-23 — — EP disclosed
EP-2010530-A2 METHODS FOR THE PREPARATION OF IMIDAZOLE-CONTAINING COMPOUNDS Novartis AG (CH) 2009-01-07 — — EP disclosed
EP-2010537-A1 IMIDAZOQUINOXALINE COMPOUNDS AS IMMUNOMODULATORS Novartis AG (CH) 2009-01-07 — — EP disclosed
EP-2007765-A2 IMMUNOPOTENTIATING COMPOUNDS Novartis AG (CH) 2008-12-31 — — EP disclosed
EP-1909564-A2 SMALL ANIMAL MODEL FOR HCV REPLICATION Novartis AG (CH) 2008-04-16 — — EP disclosed
WO-2007109812-A2 IMMUNOPOTENTIATING COMPOUNDS NOVARTIS AG (CH) 2007-09-27 — — WO disclosed
WO-2007109810-A2 METHODS FOR THE PREPARATION OF IMIDAZOLE-CONTAINING COMPOUNDS NOVARTIS AG (CH) 2007-09-27 — — WO disclosed
WO-2007109813-A1 IMIDAZOQUINOXALINE COMPOUNDS AS IMMUNOMODULATORS NOVARTIS AG (CH) 2007-09-27 — — WO disclosed
EP-1784180-A2 2-AMINO 1H IMIDAZO RING SYSTEMS AND METHODS 3M INNOVATIVE PROPERTIES COMPANY (US) 2007-05-16 — — EP disclosed
WO-2007011777-A2 SMALL ANIMAL MODEL FOR HCV REPLICATION NOVARTIS AG (CH) 2007-01-25 — — WO disclosed
WO-2006029115-A2 2-AMINO 1H IMIDAZO RING SYSTEMS AND METHODS 3M INNOVATIVE PROPERTIES COMPANY (US) 2006-03-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220340645-A1 RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME RNASEL, TIMCC, RNGTT QTRT1 1342/4885TYMS 1192/4885TLR7 349/4885
US-20230303669-A1 RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME RNASEL, TIMCC, RNGTT QTRT1 1342/4885TYMS 1192/4885TLR7 349/4885
US-11827694-B2 RSV F protein compositions and methods for making same RNASEL, TIMCC, RNGTT QTRT1 1342/4885TYMS 1192/4885TLR7 349/4885
US-20230357370-A1 RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME RNASEL, TIMCC, RNGTT QTRT1 1342/4885TYMS 1192/4885TLR7 349/4885
US-20230348575-A1 RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME RNASEL, TIMCC, RNGTT QTRT1 1342/4885TYMS 1192/4885TLR7 349/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.